This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fery, F. Articles by Balasse, E. O. Search for Related Content PubMed PubMed Citation Articles by Fery, F. Articles by Balasse, E. O.

Inhibition of Lipolysis Stimulates Whole Body Glucose Production and Disposal in Normal Postabsorptive Subjects¹

Laboratory of Experimental Medicine and Department of Endocrinology, Hôpital Erasme, University of Brussels, Brussels, Belgium

Address all correspondence and requests for reprints to: Dr. Françoise Féry, Laboratory of Experimental Medicine, University of Brussels, 808 route de Lennik, B-1070 Brussels, Belgium.

The role played by circulating free fatty acids (FFA) and fat oxidation in the regulation of whole body glucose production and uptake in the basal state is still a matter of debate. This question was analyzed in nine normal overnight fasted volunteers in whom glucose kinetics ([3-³H]glucose infusion) and substrate oxidation rates (indirect calorimetry) were measured during 10.5 h both under placebo conditions and during experimental antilipolysis induced by Acipimox given orally during the last 8 h of the study. During the last 2 h of the tests, the following mean changes () from baseline were recorded in Acipimox vs. placebo studies: FFA, -0.26 ± 0.08 vs. +0.29 ± 0.06 mmol/L (P < 0.001); glucose, -12 ± 2 vs. -12 ± 1 mg/dL (P > 0.05); glucose production, +16 ± 5 vs. -15 ± 3 mg/min (P < 0.001); C peptide, -1.11 ± 0.10 vs. -0.66 ± 0.10 ng/mL (P < 0.001); glucagon, +64 ± 25 vs. +21 ± 9 pg/mL (P < 0.05); GH, +37 ± 9 vs. +4 ± 2 ng/mL (P < 0.007); cortisol, +37 ± 25 vs. -30 ± 26 ng/mL (P < 0.04). Acipimox inhibited fat oxidation (-18 ± 4 vs. +19 ± 4 mg/min; P < 0.001) and enhanced carbohydrate oxidation (+18 ± 8 vs. - 24 ± 11 mg/min; P < 0.02). Protein catabolism calculated over the 8-h study period was significantly stimulated (+5.7 ± 2.5 vs. -1.9 ± 1.7 g/8 h; P < 0.02). During the Acipimox studies, the increased protein breakdown could theoretically account for about 75% of the increased glucose production. Thus, contrary to current opinion, FFA suppression stimulates glucose production and whole body glucose disposal in normal overnight fasted subjects.

This article has been cited by other articles:

				M. H. Vickers, P. L. Hofman, P. D. Gluckman, P. E. Lobie, and W. S. Cutfield Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1212 - E1219. [Abstract] [Full Text] [PDF]

				H. van Thien, G. J. Weverling, M. T. Ackermans, N. canh Hung, E. Endert, P. A. Kager, and H. P. Sauerwein FFAs are not involved in regulation of gluconeogenesis and glycogenolysis in adults with uncomplicated P. falciparum malaria Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E609 - E615. [Abstract] [Full Text] [PDF]

				H. Norrelund, K. S. Nair, S. Nielsen, J. Frystyk, P. Ivarsen, J. O. L. Jorgensen, J. S. Christiansen, and N. Moller The Decisive Role of Free Fatty Acids for Protein Conservation during Fasting in Humans with and without Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4371 - 4378. [Abstract] [Full Text] [PDF]

				S. Nielsen, N. Moller, S. B. Pedersen, J. S. Christiansen, and J. O. L. Jorgensen The Effect of Long-Term Pharmacological Antilipolysis on Substrate Metabolism in Growth Hormone (GH)-Substituted GH-Deficient Adults J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3274 - 3278. [Abstract] [Full Text] [PDF]

				G. F. Lewis, A. Carpentier, K. Adeli, and A. Giacca Disordered Fat Storage and Mobilization in the Pathogenesis of Insulin Resistance and Type 2 Diabetes Endocr. Rev., April 1, 2002; 23(2): 201 - 229. [Abstract] [Full Text] [PDF]

				S. Nielsen, N. Moller, J. S. Christiansen, and J. O.L. Jorgensen Pharmacological Antilipolysis Restores Insulin Sensitivity During Growth Hormone Exposure Diabetes, October 1, 2001; 50(10): 2301 - 2308. [Abstract] [Full Text]

				S. D. Mittelman and R. N. Bergman Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin Am J Physiol Endocrinol Metab, September 1, 2000; 279(3): E630 - E637. [Abstract] [Full Text] [PDF]